Stomatitis - Pipeline Insight, 2021

DelveInsights, Stomatitis Pipeline Insight, 2021, report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Stomatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage

Stomatitis Understanding
Stomatitis: Overview
Stomatitis refers to inflammation of the mucous membrane of the mouth, including the inner aspect of the lips, cheeks, gums, tongue and throat. It is a type of mucositis. It can be acute or chronic, mild or serious. Stomatitis results in pain, stinging and soreness. It can present with: Red patches, Mouth ulcers, Blisters, Peeling, Swelling, Oral dysaesthesia (numbness), Burning mouth syndrome soreness despite normal appearance. Stomatitis can be due to injury, infection, and allergy, systemic or skin disease. Many cases of stomatitis, especially canker sores or cold sores, can be diagnosed through a physical exam and a medical history including a history of symptoms. Some cases of stomatitissuch as a mild case of canker soresrequire no treatment. If treatment is required for stomatitis, it will depend on the underlying cause. Treatment for the condition includes: over-the-counter (OTC) pain relievers such as acetaminophen or ibuprofen, topical medications that help with pain or inflammation, drinking more fluids to keep the mucous membranes well hydrated, mouthwashes such as salt water (alcohol-based mouthwash should be avoided), antiviral creams for cold stores are available over-the-counter.

"Stomatitis - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Stomatitis pipeline landscape is provided which includes the disease overview and Stomatitis treatment guidelines. The assessment part of the report embraces, in depth Stomatitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Stomatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Stomatitis R&D. The therapies under development are focused on novel approaches to treat/improve Stomatitis.

Stomatitis Emerging Drugs Chapters
This segment of the Stomatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Stomatitis Emerging Drugs
GC4419: Galera Therapeutics
GC4419, also known as avasopasem manganese, has successfully completed two clinical trials in which it was evaluated for reduction of severe oral mucositis in patients with head and neck cancer undergoing radiation therapy and also receiving cisplatin, a chemotherapy drug. Avasopasem is designed to rapidly and selectively convert superoxide to hydrogen peroxide and oxygen, protecting normal tissue from damage associated with radiation therapy. Left untreated, elevated superoxide can damage noncancerous tissues and lead to debilitating side effects, including oral mucositis (OM), which can limit the anti-tumor efficacy of radiation therapy. It is currently being investigated in phase III clinical trials for stomatitis.

EC-18: Enzychem Lifesciences
EC-18 is an immune modulator, which has an unique mechanism of action called PETA (Pattern Recognition Receptor Endocytic Trafficking Accelerator) which accelerates the PRR-mediated endocytosis, endosome formation, ROS generation and recycle of PRRs such as TLR3, 4 and 7 etc. so that EC-18 shortens the duration of inflammatory immune response by quickly removing the PAMP/DAMP associated danger signals. As a result of the early termination of immune response, EC-18 contributes the rapid resolution of inflammation and early return to homeostasis. The clinical trials for EC-18 are in phase II stage for the treatment of patients with chemo radiation induced oral mucositis.

IZN-6N4: Izun Pharmaceuticals
IZN-6N4, is designed to prevent and treat SOM in head and neck cancer patients. SOM, which occurs in about 70% of these patients, comprises the painful and debilitating ulcerated sores that develop in the mouth and throat of radiation therapy patients. IZN-6N4 has shown strong efficacy in preventing the incidence of SOM and reducing undesirable side effects in its completed Phase II trial, and Izun anticipates initiating its Phase III trial in the second half of 2021.
Further product details are provided in the report..

Stomatitis: Therapeutic Assessment
This segment of the report provides insights about the different Stomatitis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Stomatitis
There are approx. 15+ key companies which are developing the therapies for Stomatitis. The companies which have their Stomatitis drug candidates in the most advanced stage, i.e. Phase III include, Galera Therapeutics.
Phases
DelveInsights report covers around 15+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration
Stomatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical.
Molecule Type

Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Stomatitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Stomatitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Stomatitis drugs.

Stomatitis Report Insights
Stomatitis Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

Stomatitis Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Stomatitis drugs?
How many Stomatitis drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Stomatitis?
What are the key collaborations (IndustryIndustry, IndustryAcademia), Mergers and acquisitions, licensing activities related to the Stomatitis therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Stomatitis and their status?
What are the key designations that have been granted to the emerging drugs?

Introduction
Executive Summary
Stomatitis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
GC4419: Galera Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
EC-18: Enzychem Lifesciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early stage products (Phase I/II)
Comparative Analysis
Melatonin oral gel: Spherium Biomed
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Stomatitis Key Companies
Stomatitis Key Products
Stomatitis- Unmet Needs
Stomatitis- Market Drivers and Barriers
Stomatitis- Future Perspectives and Conclusion
Stomatitis Analyst Views
Stomatitis Key Companies
Appendix

List Of Tables

Table 1 Total Products for Stomatitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List Of Figures

Figure 1 Total Products for Stomatitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available